Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

Stock Information for Crescent Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Crescent Biopharma Inc.

Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Crescent Biopharma to Present at November Investor Conferences
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.